All News
Gout Undertreatment Persists
Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
Read Article
The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination
At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?
Read Article
Is Pain Control by Cannabis an Option?
An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.
Read Article
Time to consider gender stratification in AxSpA diagnosis and management
Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.
Read Article
BSR Guideline for Psoriatic Arthritis - 2022 Update
The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
TheDaoIndex KDAO2011 ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links: